Perfluorocarbon Enhanced Glasgow Oxygen Level Dependent (GOLD) magnetic resonance metabolic imaging identifies the penumbra following acute ischemic stroke by Deuchar, Graeme A. et al.






2018; 8(6): 1706-1722. doi: 10.7150/thno.21685 
Research Paper 
Perfluorocarbon Enhanced Glasgow Oxygen Level 
Dependent (GOLD) Magnetic Resonance Metabolic 
Imaging Identifies the Penumbra Following Acute 
Ischemic Stroke 
Graeme A Deuchar1,3, David Brennan2,3, William M Holmes1, Martin Shaw4, I Mhairi Macrae1, Celestine 
Santosh2,3 
1. Glasgow Experimental MRI Centre, Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow 
2. Department of Neuroradiology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK 
3. Aurum Biosciences Ltd, 20-23 Woodside Place, Glasgow, G3 7QL 
4. Clinical Physics, University of Glasgow, Western Infirmary, Glasgow, United Kingdom 
 Corresponding author: Dr Graeme Deuchar, Aurum Biosciences Ltd, 20-23 Woodside Place, Glasgow, G3 7QL, Scotland, UK. Tel: +44 141 582 1212; Email: 
gdeuchar@aurumbiosciences.com 
© The authors. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license 
(https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.06.29; Accepted: 2017.12.16; Published: 2018.02.12 
Abstract 
The ability to identify metabolically active and potentially salvageable ischaemic penumbra is crucial 
for improving treatment decisions in acute stroke patients. Our solution involves two 
complementary novel MRI techniques (Glasgow Oxygen Level Dependant (GOLD) Metabolic 
Imaging), which when combined with a perfluorocarbon (PFC) based oxygen carrier and hyperoxia 
can identify penumbra due to dynamic changes related to continued metabolism within this tissue 
compartment. Our aims were (i) to investigate whether PFC offers similar enhancement of the 
second technique (Lactate Change) as previously demonstrated for the T2*OC technique (ii) to 
demonstrate both GOLD metabolic imaging techniques working concurrently to identify penumbra, 
following administration of Oxycyte® (O-PFC) with hyperoxia.  
Methods: An established rat stroke model was utilised. Part-1: Following either saline or PFC, 
magnetic resonance spectroscopy was applied to investigate the effect of hyperoxia on lactate 
change in presumed penumbra. Part-2; rats received O-PFC prior to T2*OC (technique 1) and MR 
spectroscopic imaging, which was used to identify regions of tissue lactate change (technique 2) in 
response to hyperoxia. In order to validate the techniques, imaging was followed by 
[14C]2-deoxyglucose autoradiography to correlate tissue metabolic status to areas identified as 
penumbra. 
Results: Part-1: PFC+hyperoxia resulted in an enhanced reduction of lactate in the penumbra when 
compared to saline+hyperoxia. Part-2: Regions of brain tissue identified as potential penumbra by 
both GOLD metabolic imaging techniques utilising O-PFC, demonstrated maintained glucose 
metabolism as compared to adjacent core tissue. 
Conclusion: For the first time in vivo, enhancement of both GOLD metabolic imaging techniques 
has been demonstrated following intravenous O-PFC+hyperoxia to identify ischaemic penumbra. 
We have also presented preliminary evidence of the potential therapeutic benefit offered by O-PFC. 
These unique theranostic applications would enable treatment based on metabolic status of the 
brain tissue, independent of time from stroke onset, leading to increased uptake and safer use of 
currently available treatment options. 










Recent data from the global burden of disease 
2013 study reveal that every year ~6.5 million people 
die as a result of stroke worldwide [1] making it the 
second leading cause of death [2]. A further 5 million 
people worldwide who survive stroke are left 
permanently disabled with significant long term 
clinical and social impact on patients lives 
(http://www.worldstrokecampaign.org). The global 
burden of stroke continues to escalate with an ageing 
population being associated with a 62% increase in 
global death rate between 1990 – 2013 [3]. This 
highlights the need for improvements in the 
management of stroke patients in order to tackle this 
growing unmet medical need.  
The restoration of blood flow through 
thrombolytic therapy by administration of 
recombinant tissue plasminogen activator (rtPA) to 
break down the clot during the first 4.5 h from stroke 
onset has resulted in benefit for acute ischaemic stroke 
(AIS) patients [4]. The recent emergence of successful 
mechanical thrombectomy, which utilises clot 
retrieval devices to remove the obstruction from 
proximal cerebral arteries thereby restoring blood 
flow, represents the first major advance in treatment 
options for acute ischaemic stroke in last 20 years 
[5,6]. However at present this is only suitable in 
selected patients and requires rapid access to 
specialist neuorinterventional centres, meaning that 
clinical use is currently limited. In both instances the 
benefit gained from successful reperfusion is due to 
the presence of hypoperfused, metabolically active 
ischaemic penumbra tissue, the salvage of which is 
associated with a better outcome [7]. 
Overall current treatment rates for AIS remain 
poor with ~75% of patients being excluded from 
thrombolytic treatment where stroke onset time is 
unknown, has exceeded 4.5hours or where there is 
risk-benefit uncertainty. However, many patients 
excluded on the basis of information on stroke onset 
time are likely to have potentially salvageable 
penumbral tissue [8]. Of further concern, treatment 
decisions based largely on time could result in some 
patients being treated by thrombolysis within 4.5 h 
who have little or no penumbra, thereby placing 
patients at increased risk of intracranial haemorrhage 
with little or no potential for clinical benefit.  
Accurate identification of the salvageable 
ischaemic penumbra is crucial for improving 
treatment decisions in AIS patients. However, the 
current lack of an easily applied and accurate imaging 
technique enabling reliable identification of 
salvageable penumbral tissue acutely following stroke 
has hampered progress in attempts to improve the 
management of patients.  
Currently, non-contrast computed tomography 
is used to quickly evaluate suspected stroke patients 
to discriminate between ischaemic and haemorrhagic 
stroke and to exclude stroke mimics [9]. However it is 
insensitive to early changes associated with brain 
ischaemia and offers no insight into the existence or 
absence of potentially salvageable penumbral tissue.  
Current advanced brain imaging techniques 
including MRI-based perfusion/diffusion (DWI/PI) 
mismatch and CT perfusion (CTP) lack accuracy and 
do not provide direct assessment of tissue metabolic 
status. Both techniques have already been applied to 
select patients for acute stroke clinical trials based on 
“penumbra” imaging. However neither technique, 
which rely on selecting threshold values to define the 
DWI lesion and the perfusion deficit, have as yet been 
validated and accepted for clinical use as routine for 
penumbra imaging. This lack of validated thresholds 
leads to difficulties in accurately differentiating 
penumbra from irreversibly damaged core and 
benign oligaemic tissue, destined to survive [10,11,12]. 
There is no practical method that gives information on 
ischaemic brain tissue's ability to metabolically use 
oxygen, as aerobic metabolism is the critical indicator 
of whether the penumbra will survive. The 
availability of new improved diagnostic and 
therapeutic options for the management of acute 
ischaemic stroke represents an urgent clinical need.  
Our group have been developing GOLD 
(Glasgow Oxygen Level Dependent) diagnostic 
imaging, which comprises two independent but 
complementary MRI based techniques combined with 
therapeutic potential to extend the lifespan of 
penumbral tissue. The MRI sequences when 
combined with an oxygen challenge (OC; 100% 
inhaled oxygen) identify the ischaemic penumbra by 
identifying aerobic metabolism within the 
hypoperfused ischaemic tissue compartment [13,14]. 
Technique 1 utilises a Blood Oxygen Level Dependent 
(BOLD) T2* signal based on the different magnetic 
properties of deoxy- and oxyhaemoglobin in blood 
(paramagnetic and diamagnetic, respectively) and 
this technique has been shown to identify a region 
within the perfusion deficit in rodent stroke models 
that displays several features of penumbra: 
histological evidence of normal neuronal 
morphology, ongoing glucose metabolism, and tissue 
recovery on prompt reperfusion [13,15,16]. This 
T2*OC technique has already shown potential for 
clinical translation in stroke patients [17]. However, 





signal-to-noise was poor due to the limitation in the 
amount of oxygen that could be delivered to the 
tissues and the presence of 100%O2 within the 
paranasal sinuses which caused artefacts of 
T2*-weighted images, due to the paramagnetic effect 
of oxygen. The technique has also been successfully 
reproduced pre-clinically by another group [18]. 
Technique 2 uses the novel concept of lactate 
change imaging, which can compartmentalise brain 
tissue based on the ability to identify tissues 
displaying anaerobic metabolism but having the 
potential for aerobic metabolism with increased 
oxygen delivery [14] therefore indicating the tissue as 
potentially salvageable. Proof of principle for lactate 
change imaging was also demonstrated with an OC of 
100% oxygen alone but again there were issues 
regarding sensitivity and time required to produce 
lactate change [14], limitations associated with the 
amount of oxygen that could be delivered to the 
tissues using hyperoxia alone. 
To increase the amount of oxygen delivered to 
the tissues we have continued to develop GOLD 
imaging using an approach where an intravenous 
oxygen carrier perfluorocrabon (PFC) is administered 
prior to OC. In addition, unlike other advanced brain 
imaging techniques, additional imaging time carries 
no penalty (“time lost is brain lost”) [19] since 
PFC+oxygen has the potential to maintain brain 
viability and reduces ischaemic damage. GOLD 
diagnostic imaging would replace a reliance on the 
time clock and replacing it with a metabolic tissue 
clock based on identifying patients who still have a 
significant volume of penumbra, so that many more 
patients could benefit from current treatments. It 
would also enable identification of patients who do 
not have existing penumbra within current treatment 
windows for acute stroke, where the benefit-risk 
balance doesn’t justify the use of thrombolysis thus 
avoiding the unnecessary risk of fatal haemorrhage.  
Perfluorocarbons (PFCs) are fluorinated 
hydrocarbons with respiratory gas carrying capacity 
superior to that of haemoglobin [20]. They are 
hydrophobic in nature and therefore have to be 
emulsified for intravenous use. PFC particle size 
within emulsions is very small (~0.2 μm compared to 
~7 μm for erythrocytes), enabling better penetration 
through the microcirculation (capillary size ~7 μm) 
improving oxygen supply to poorly perfused tissue. 
These characteristics coupled with the release of 
oxygen by simple diffusion down a partial pressure 
gradient make PFCs ideal agents by delivering more 
oxygen to the ischaemic tissues and so overcoming 
the current limitations of translating both GOLD 
imaging techniques for diagnostic evaluation in the 
acute stroke setting. Having initially designed and 
produced our own bespoke PFC emulsion (b-PFC), 
which was used in study 1 we subsequently 
established a strategic collaboration to develop 
Oxycyte® (O-PFC) intravenous emulsion, which is a 
clinical stage PFC emulsion. This would accelerate the 
translation of our acute stroke programme as this 
product has already undergone significant pre-clinical 
safety/toxicology and early human trial work in 
traumatic brain injury.  
We have previously demonstrated enhanced 
detection of penumbra with T2*OC using our b-PFC 
combined with a lower level (40%) of inhaled oxygen 
[21]. Therefore, the addition of PFC to OC has 
demonstrated potential to overcome the limitations 
encountered in early clinical studies. 
The primary aims of the current studies were to 
(i) determine whether our lactate change technique 
could also be enhanced by accelerating the change 
with the addition of intravenous PFC (ii) investigate 
the potential of combining the metabolic GOLD 
imaging techniques (T2*OC and Lactate Change) 
within a single scanning protocol, with confirmation 
of ongoing glucose metabolism in regions identified 
as penumbra using [14C]2-deoxyglucose 
autoradiography. A secondary aim was to investigate 
the therapeutic potential of the enhanced oxygen 
delivery to the compromised penumbra by addition 
of intravenous PFC in combination with hyperoxia.  
Materials & Methods 
Model of Middle Cerebral Artery Occlusion 
(MCAO) 
Experiments were performed under license from 
the UK Home Office, were subject to the Animals 
(Scientific Procedures) Act, 1986 and were approved 
by the University Ethical Review Panel. Experiments 
have been carried out and reported in accordance 
with the ARRIVE (Animal Research: Reporting In 
Vivo Experiments) guidelines. Male Sprague Dawley 
rats (327 ± 26 g, n=24), Harlan, Bicester, UK) had free 
access to food and water and were maintained on a 12 
h light-dark cycle. Isoflurane (5%) in N2O:O2 
(70%:30%) was used for induction of anaesthesia and, 
following tracheostomy, was lowered during further 
surgery (2.5-3%) and maintenance of animal 
throughout the protocol (2-2.5%). N2O:O2 was 
replaced with medical air supplemented with ~5% O2 
(26% O2: normoxia) prior to middle cerebral artery 
occlusion (MCAO). Animals were artificially 
ventilated and body temperature maintained at 37°C. 
Femoral arteries were cannulated (Portex: external 
diameter 0.96 mm; internal diameter 0.58 mm) for 
mean arterial blood pressure (MABP) measurement 
and blood gas analysis in order to maintain 





physiological stability. A femoral vein was cannulated 
for administration of the PFC emulsion or saline. 
MABP and heart rate were continuously recorded 
(AcqKnowledge, Biopac Systems, CA, USA). 
Permanent MCAO was induced with an intraluminal 
filament. A 3.0 uncoated nylon filament with a 
heat-induced bulb at the tip (~320-340 µm in 
diameter) was advanced along the left internal carotid 
artery for ~20-21 mm from the bifurcation of the 
external carotid artery until resistance was felt. 
Following MCAO rats were transferred, under the 
same anaesthetic, directly into the magnet bore, fully 
instrumented for monitoring and control of 
physiological variables (blood pressure, temperature 
and blood gases). Successful MCAO was confirmed 
from the initial diffusion-weighted imaging (DWI) 
and perfusion imaging (PI) MRI scans.  
Although permanent MCAO (pMCAO) may not 
be representative of many ischaemic stroke patients it 
represents the best model for these preclinical proof of 
concept studies developing and validating the 
diagnostic techniques used for identifying penumbra. 
The pMCAO model displays less heterogeneity in the 
initial lesion size when compared to the transient 
filament or embolic MCAO models also utilized by 
our group. In our experience this model shows 
evidence from previously published work of a 
significant amount of penumbral tissue, which 
gradually becomes incorporated into the ischaemic 
core over the first 4-6 h following stroke [13,15,16]. 
Magnetic Resonance Imaging Scanning 
MRI was performed on a Bruker Biospec 7T/30 
cm system (Bruker Biospin, Ettlingen, Germany) 
equipped with an inserted gradient coil (121 mm ID, 
400 mT/m) and a 72 mm birdcage resonator. 
Following stroke surgery, the animals were placed in 
a rat cradle with head secured in position using ear 
and tooth bars to restrict movement. Brain imaging 
was acquired using a surface coil placed above the 
head. For Study 1 we utilised localised H1 Magnetic 
Resonance spectroscopy (MRS) in combination with 
DWI and PI using a 2 cm linear surface receiver coil. 
For Study 2 (spectroscopic imaging) a 4-channel 
phased array coil was used which enabled novel 
spectroscopic imaging of brain lactate levels 
consecutively with DWI, PI and T2*.  
Diffusion weighted imaging (Study 1 and 2) 
DWI was employed to identify acute ischaemic 
damage: For quantitative determination of the 
apparent diffusion coefficient (ADC) a 4-shot spin 
echo planar imaging (EPI) diffusion weighted scan 
(echo time: 22.5 ms, repetition time: 4000.3 ms, 4 
averages, matrix: 96 x 96, FOV: 25 x 25 mm, 3 
directions: x, y, z, B values: 0, 1000 s/mm2, 8 
contiguous coronal slices of 2.0 mm thickness, 4 shot 
EPI) was used for quantitative determination of the 
ADC.  
Perfusion Imaging (Study 1 and 2) 
PI was employed to identify the blood flow 
deficit: Non-invasive, relative cerebral blood flow 
(CBF) measurements were carried out within the 
MCA territory using a form of pseudo-continuous 
arterial spin labelling (ASL) based on a train of 
adiabatic inversion pulses [22]. The sequence employs 
a spin-echo EPI imaging module (echo time: 20 ms, 
repetition time: 7000 ms, matrix 96 x 96, FOV 25 x 25 
mm, slice thickness 2.0 mm, 16 averages, 4 shots) 
preceded by 50 hyperbolic secant inversion pulses in a 
3 second train.  
Localised Magnetic Resonance Spectroscopy (Study 1) 
Localised 1H spectra were acquired using a point 
resolved spectroscopy sequence (PRESS) (echo time, 
20 ms; repetition time, 3000 ms). Voxels of 4 x 4 x 4 
mm3 were placed in the ischemic region, defined by 
DWI and homotopic contralateral caudate nucleus. 
Spectra were acquired with 16 averages. A smaller 
voxel 2.5 x 2 x 4 mm3 was placed in the cortical 
DWI/PI mismatch region. To increase the signal noise 
ratio, 90 averages were acquired. The time taken to 
acquire a block of three spectra for the three distinct 
regions of interest (ROIs) was 10 minutes.  
Spectroscopic Lactate Imaging (Study 2) 
Spectroscopic imaging of lactate was performed 
using a novel pulse sequence specifically designed to 
efficiently image changes in lactate within the brain 
[14]. For the current study, this sequence was 
designed to acquire data from a single slice, although 
it should be adaptable to multi-slice acquisition for 
future development. A three-pulse CHESS module 
was used for water suppression. For excitation, a 
frequency selective 6 ms Gaussian pulse was used 
with a bandwidth of 452 Hz centered at 1.06 ppm. 
This frequency range includes lactate, lipid and 
macromolecular resonances, and as such, acquires a 
composite image. As the frequency selective pulse 
excites lipids outside of the brain (e.g. subcutaneous 
fat), it is necessary to use outer volume suppression 
around the brain to avoid saturating the signal of 
interest from within the brain. The selected signal was 
then imaged using a RARE imaging module (echo 
time, 14.5 ms; repetition time, 2800 ms, 256 averages; 
field of view, 1.5_2.0 cm2; 42 x 64 matrix; resolution, 
357 mm x 390 mm; slice thickness, 2 mm; RARE factor, 
32). Scan time was 12 min.  






Figure 1. Apparent diffusion coefficient rat brain image illustrating thresholded DWI (white, ischaemic core)/PI mismatch (black, presumed penumbra) with the 
placement of the voxels for localised MRS (Study 1). DWI: diffusion-weighted imaging; PI: perfusion imaging; MRS: magnetic resonance spectroscopy. 
 
T2* scanning (Study 2) 
The T2* sequence was a single shot, gradient 
echo (EPI) sequence (echo time, 20 milliseconds; 
repetition time, 10 s; matrix 96_96, field of view, 25_25 
mm, 8 contiguous slices, 1.5 mm thick, 2 averages, 
temporal resolution 20 s, 75 repetitions). Two coronal 
slices within middle cerebral artery territory were 
selected to generate T2* signal change maps, which 
were used to generate the mean signal change for each 
region of interest (ROI) across the two slices. 
Penumbra tissue was defined using a threshold based 
on the empirical rule: tissue displaying a mean 
increase in T2*, which was greater than two standard 
deviations above the contralateral cortex mean. 
Perfluorocarbon intravenous emulsion 
For Study 1 we used an in-house designed PFC 
emulsion including perfluorodecalin (C10F18) (F2 
Chemicals Ltd, UK), which is known to have an 
oxygen solubility of 49 ml/100 ml of aqueous PFC at 
standard temperature and pressure. This bespoke 
PFC emulsion (b-PFC) was emulsified for i.v. use in a 
phosphate buffered solution containing (4% w/v) 
purified egg yolk lecithin (Lipoid 80 S Egg Lecithin, 
Ludwigshafen, Germany). The final emulsion for i.v. 
use was 40% w/v perfluorodecalin and was prepared 
by Professor Julian Eastoe, an expert in emulsion 
chemistry at the University of Bristol. The mean 
droplet diameter within the emulsion, analysed using 
dynamic light scattering was shown to be similar to 
that reported in the literature (~0.2µm).  
With an objective of progressing into clinical 
trials investigating the potential of GOLD in acute 
stroke patients, and recognising the lengthy and 
costly process of developing a bespoke PFC emulsion 
as a new pharmaceutical, we entered into 
collaborative agreements with Tenax Therapeutics Inc 
(formerly Oxygen Biotherapeutics) to use the PFC 
emulsion Oxycyte® (O-PFC) in our acute stroke 
development programme. O-PFC had already 
undergone significant non-clinical safety assessment 
and had been used in early human trial work where it 
progressed into a Phase 2b trial in traumatic brain 
injury (NCT00908063). Therefore, the use of O-PFC in 
the ongoing non-clinical activities would offer 
obvious benefits in expediting the development 
pathway for our GOLD imaging technology and this 
was the PFC emulsion used in Study 2 investigating 
the feasibility of combined lactate change and T2* OC 
imaging. 
Experimental protocol for Study 1: Localised 
Spectroscopy to measure Lactate Change in 
Penumbra 
Following transfer into the magnet bore a period 
of stabilisation (~20 min) was allowed during which 
arterial blood gases, blood pressure, ECG and 
respiration were monitored to ensure haemodynamic 
stability and values within the normal physiological 
range. Stroke success was confirmed using initial PI 
and DWI scans with initial perfusion and ADC maps 
used to position voxels within the regions of interest 
(ROIs) in the ischaemic core, homotopic contralateral 
caudate nucleus and DWI/PI mismatch region 
(approximate penumbra, Figure 1)). Localised 1H 
spectroscopy, was used to investigate changes in the 
metabolite spectra. Initial baseline spectra were 
acquired for each voxel with the animal ventilated on 
air up to a point where there appeared to be an 
increase in the lactate peak within the penumbra 
voxel. During this baseline period further DWI scans 
were acquired, enabling the generation ADC maps at 
regular intervals. This was done to ensure that the 
penumbra voxel had not incorporated tissue 
consistent with ischaemic core.  
When an increase in the lactate peak was 
observed in the penumbra voxel, b-PFC (1.5 mL, n=7) 
or saline (1.5 mL, n=8) was administered 
intravenously. The fraction of inspired oxygen (FiO2) 
was subsequently increased to ~100% for 30 minutes 
during which 3 blocks of spectra were acquired for 
each ROI voxel. Ventilation was then switched back to 
normoxia for 30 minutes and a further 3 blocks of 





spectra acquired for each ROI voxel. ADC maps were 
acquired at regular intervals during the experiment 
including at baseline prior to 100% O2, following 30 
minutes 100% O2 and following 30 minutes with the 
animal returned to normoxic ventilation. This also 
allowed for an assessment of change in lesion volume 
during the experimental protocol.  
The spectra were processed individually with 
TopSpin™ (Bruker Biospin, Rheinstetten, Germany) 
using automatic phasing and automatic baseline 
correction. The change in lactate at each time point 
following both 100% O2 and upon returning to 
normoxic ventilation was determined from the 
change in the 1H spectra integral between 1.2 ppm 
and 1.9 ppm (measured using Area Under the Curve; 
AUC). 
Experimental protocol for Study 2: Combined 
T2* and Lactate Change OC GOLD Imaging 
techniques to identify the penumbra. 
Following permanent MCAO in rats (n=9) 
animals were transferred into the magnet bore 
(Bruker 7T Biospec) and there was a period of 
stabilisation, during which blood pressure, ECG and 
respiration were monitored to ensure haemodynamic 
stability and values within the normal physiological 
range. The MRI scanning protocol is shown in Figure 
2. During the initial hour after MCAO, DWI and PI 
were carried out to confirm the presence of ischaemic 
injury and cerebral blood flow deficit, respectively. 
Spectroscopic imaging was used to spatially identify 
regions where changes in tissue lactate occurred in 
response to periods of hyperoxia. Following initial 
DWI/PI scans a water image was acquired using the 
spectroscopic imaging sequence (bandwidth 452Hz, 
centered at 4.7ppm) and this was used during analysis 
for lactate image registration.  
The combined T2*OC / Lactate Change OC 
penumbra imaging protocol (Figure 2) was carried 
out as follows. With the animal on normoxic 
ventilation, an initial baseline lactate spectroscopic 
image (single coronal slice) was acquired within 
middle cerebral artery territory that was predicted 
from a previous study [21] to match approximately to 
where the T2* signal change maps would be 
generated. At a mean time of 75 minutes following 
MCAO, animals were administered 1.5 ml (~4.5 
ml/kg, IV) O-PFC as a slow bolus over 6 minutes. 
Next, the first oxygen challenge T2* scan was acquired 
at a mean time of 86 minutes after stroke onset: 
following 3 minutes of scanning for baseline 
(normoxia), O2 was increased to 50% for a period of 6 
minutes and then increased to 100% for a further 6 
minutes. Ventilation was kept on 100% O2 and a 
further lactate spectroscopic image was acquired. The 
animal was then returned to normoxic ventilation and 
allowed a period of stabilisation (~20 minutes) to 
return to normal physiological parameters. This 
protocol of OC during lactate change spectroscopic 
imaging and T2* was then repeated (mean time for 
second T2* scan was 160 minutes following MCAO. 
Additional DWI and PI scans were taken throughout 
the protocol.  
[14C]2-Deoxyglucose (2-DG) in vivo autoradiography 
At the end of the MRI scanning session, animals 
were quickly removed from the magnet, and returned 
to the operating theatre where a bolus of [14C]2-DG 
was injected intravenously at a steady rate over 30 
seconds (125 mCi/kg in 0.6mL heparinized saline, 
Perkin-Elmer, Waltham, MA, USA). Plasma glucose 
and [14C] were analyzed from 14 timed arterial blood 
samples over 45 minutes by glucose oxidase assay and 
liquid scintillation analysis, respectively. At 45 
minutes, animals were killed by intravenous injection 
of sodium pentobarbitone and the brains quickly 
dissected out, frozen (isopentane, -40°C) and 
processed for quantitative autoradiography. Coronal 
cryostat sections (20 µm) were exposed to X-ray film 
(Kodak Biomax MR film, Eastman Kodak Company, 
Rochester, NY, USA) for 3 days with a set of [14C] 
standards (Amersham Biosciences, GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). 
Autoradiograms were analyzed using a computer 
digitized image analysis system (MCID v4, Interfocus, 
Linton, Cambridge, UK). Quantitative optical density 
 
 
Figure 2. Schematic time line for Study 2 MRI protocol. Baseline scans aquired under normoxic ventilation (AIR) included DWI and PI to confirm stroke and a basal 
lactate scan (LSI). Following administration of O-PFC, the initial OC (50% O2 for 6 min and 100% O2 for 6 min) was carried out (88 min ± 13 min post-stroke) during 
which a T2* scan and a further lactate scan was acquired. The animal was subsequently returned to normoxic ventilation with further DWI, PI and lactate scans 
acquired under these conditions. A second OC was carried out (159 min ± 13 min post-stroke), during which a further T2* scan and lacate scan were acquired. DWI: 
diffusion-weighted imaging; LSI: lactate specroscopic imaging; MRI: magnetic resonance imaging; OC: oxygen challenge; PI: perfusion imaging. 





measurements were taken from four regions of 
interest (ROIs defined in detail below with an 
example shown in Figure 1iii): (1) ischemic core; (2) 
T2* defined penumbra; (3) contralateral region 
homotopic to the penumbra and (4) contralateral 
region homotopic to the ischemic core. Optical 
density values were converted into [14C] tissue 
concentrations using the calibration curve derived 
from the set of [14C] standards. The [14C] tissue 
concentrations along with the plasma glucose and 
[14C] plasma concentrations were used to calculate 
local cerebral glucose utilization (LCMRglu, mmol per 
100 g per minute) in ROIs using the operational 
equation of Sokoloff [23]. 
Glucose utilization for each ROI was generated 
from 3 autoradiographic images covering the 
rostro-caudal extent of each of the two selected 
coronal MRI slices (2 mm) used to generate the T2* 
signal change maps, which also approximated the 
slice used for lactate change maps. This enabled 
glucose utilization within each ROI to be determined 
from autoradiograms. 
Image Analysis 
ADC maps, CBF maps and T2* percentage signal 
change maps during hyperoxia and lactate 
spectroscopic images were generated using Image J 
software (http://rsb.info.nih.gov/ij/).  
Lactate Change OC maps were generated for a 
single coronal slice by subtraction of spectroscopic 
images acquired during baseline (normoxia) and 
hyperoxia with a spatial smoothing filter being 
applied. Aerobic Lactate Change maps represent the 
change in tissue lactate in response to OC following 
administration of O-PFC in Study 2. Anaerobic 
Lactate Change maps represent the change in tissue 
lactate in response to returning to ventilation with 
medical air following a period of hyperoxia. 
T2* percentage signal change was analysed on 
MRI-based ROIs, which were selected according to 
specific features on the images; (1) Ischaemic core in 
caudate nucleus within the thresholded ADC lesion; 
(2) Its mirror contralateral region manually 
designated by researcher; (3) Penumbra as defined by 
thresholded T2* percentage signal change (4) 
contralateral cortex (see Figure 7A iii). In selecting 
ROIs, the mean T2* percentage signal change (with 
standard deviation) was measured in the dorso-lateral 
contralateral cortex, avoiding any large veins and 
venous sinuses. The T2* penumbra ROI was 
automatically derived from a threshold: tissue with a 
percentage signal change ≥ the contralateral ROI 
mean + two standard deviations. The ischaemic core 
ROI was selected as a region within the thresholded 
ADC lesion for the corresponding slice. A 
representative contralateral region was manually 
drawn avoiding areas of high signal change on T2* 
maps due to the presence of large veins, meaning that 
the region was not always an exact mirror of the 
ipsilateral ROI.  
The ROIs were selected and analysed on two 
coronal slices within middle cerebral artery territory. 
T2* percentage signal change maps were produced by 
comparing the peak signal during each level of the 
hyperoxia protocol (mean taken over ~2 min 
scanning) with the mean signal during baseline (first 3 
min of scan prior to hyperoxia). The difference in 
signal was divided by the mean baseline signal and 
multiplied by 100 to give percentage signal change 
maps. Penumbra tissue was defined using a threshold 
based on the empirical rule: tissue showing a mean 
increase in T2* which was greater than 2 standard 
deviations above the contralateral cortex mean. 
Approximate penumbral tissue generated from 
DWI-PI mismatch area (Figure 7A iii) was also used 
for comparison with the regions detected as 
penumbra by T2* and Lactate Change OC imaging. 
This was done by producing quantitative ADC maps 
in units of square mm per second using the 
Stejskal-Tanner equation [24]. A reduction of 16.5% in 
ADC when compared to mean contralateral value was 
used as a threshold to determine ischaemic lesion 
volume as this has previously been reported to closely 
match final infarct size in a model of permanent 
MCAO in Sprague Dawley rats [25]. CBF maps were 
produced to identify the perfusion deficit area which 
was calculated using a threshold of a 57% reduction of 
the mean contralateral CBF [26].  
Data presentation and statistics 
All data are presented as mean ± SD. Statistical 
analysis was performed using GraphPad Prism 
(Version 4.03, CA, USA). Comparison of physiological 
variables before and during OC, and of OC-induced 
T2*signal change in penumbra, contralateral cortex 
and ischaemic core ROIs were assessed using a 
2-tailed paired Student’s t-test. Data from different 
groups were assessed using a 2-tailed unpaired 
Student’s t-test. For comparison of paired data within 
groups, such as the change in lactate levels measured 
within the penumbra voxel from Study 1, a repeated 
measures one-way ANOVA followed by a Dunnet’s 
multiple comparison test was performed. For 
comparison of unpaired data such as the magnitude 
of T2* signal change between ROI’s, a one-way 
ANOVA followed by a Bonferroni’s multiple 
comparison test was performed. For all comparisons, 
p<0.05 was considered as statistically significant. 






Study 1 Localised Spectroscopy 
Physiological Variables 
Physiological data are shown in supplementary 
Table S1. Prior to administration of either saline or 
b-PFC and the subsequent OC, physiological variables 
were within the normal physiological range. During 
both saline and b-PFC injection there was a small, 
significant increase in MABP, which had returned to a 
level not different from baseline prior to initiation of 
OC. Oxygen challenge (FiO2 ~1.0) induced a transient, 
significant increase in PaO2 of ~3.5-4.0 fold in arterial 
blood samples from both groups. This is consistent 
with previous studies using this level of hyperoxia 
[13,27]. There was a small, significant increase in 
PaCO2 observed during OC in the group receiving 
saline, prior to hyperoxia. 
Prior administration of b-PFC Improves Sensitivity of 
Lactate Change OC Imaging 
Data acquired from the ischaemic core (Figure 
3a) and contralateral caudate nucleus (Figure 3b) 
demonstrated no change in the lactate peak on the 1H 
spectra upon changing ventilation from air to 100% 
oxygen in animals receiving either PFC or saline prior 
to hyperoxia (representative spectra are shown in 
Figure 3).  
In contrast, in the penumbra voxel a reduction in 
the lactate peak was consistently observed when 
ventilation was switched from air to 100% oxygen in 
animals receiving 4.5 ml/kg b-PFC prior to hyperoxia 
(Figure 4A, 5A). However, in animals receiving saline, 
the effect on the lactate peak was more variable with 
further increases in the lactate peak observed in some 
cases (Figure 4B, 5A).  
 
 
Figure 3. Representative examples of localised 1H spectra from (A) the ischaemic core voxel and (B) the corresponding region of the contralateral hemisphere 
following MCAO in an animal administered b-PFC (4.5 mL/kg, i.v.). MCAO: middle cerebral artery occlusion.  
 
Figure 4. Representative examples of localised 1H spectra from (A) the penumbra voxel in an animal administered b-PFC (4.5 mL/kg, i.v.) and (B) the penumbra voxel 
in an animal administered saline (4.5 mL/kg, i.v.) following MCAO. MCAO: middle cerebral artery occlusion. 






Figure 5. Group mean data (with SD error bars) for (A) 30 min hyperoxia (100% O2) on lactate levels following administration of either saline (4.5 mL/kg, i.v.) or 
b-PFC (4.5 mL/kg, i.v.). (B) Same data extended to include the effect of a return to normoxic ventilation. *p<0.05 versus corresponding group base using one-way 
repeated measures ANOVA followed by Dunnett’s multiple comparison test. 
 
Figure 6. (A) Illustrative example showing ischaemic damage defined from 
thresholded ADC maps (red) progresses with time. (B) Growth of ischaemic 
damage assessed over 60 min starting ~ 90 min after stroke. Rats received 
either 4.5 mL/kg b-PFC or saline followed by 30 min hyperoxia (100% O2) then 
normoxia for 30 min. Data displayed as mean ± SD, *p<0.05. ADC: apparent 
diffusion coefficient. 
 
Penumbra lactate levels increased by 3.5% 
during 30 min hyperoxia in the control saline group 
compared with a maximum decrease of 20.8% in the 
b-PFC group (Figure 5A).  
When ventilation was switched back to air 
(Figure 5B) the lactate peak significantly increased by 
a further 32.4% within 30 min in the saline group, 
while the decrease in lactate in the b-PFC group was 
maintained below pre-hyperoxia baseline values.  
The ADC derived lesion volume measured over 
the same period revealed significantly less lesion 
expansion in the b-PFC group (28.8 ± 16.7 mm3) 
compared to the saline group (80.8 ± 27.3 mm3) 
(Figure 6). 
Study 2: Combined T2* and Lactate change 
OC GOLD Penumbra Imaging 
Physiological Variables 
Physiological data were within the normal 
physiological range prior to administration of O-PFC 
or saline and initiation of OC (supplementary Table 
S2). During administration of O-PFC there was a 
transient (~10%) increase in MABP. Following the 
completion of O-PFC administration MABP decreased 
below the pre-injection baseline but remained within 
the normal range. During hyperoxia, at both early and 
later time points, there was a similar increase in 
MABP (~15%) during 50% O2 OC with no further 
increase evident on increasing oxygen to 100%. 
Similar to Study 1 results, an approximate 4 fold 
increase in PaO2 was evident in arterial blood samples 
following 100% OC. No significant changes were 
evident in PaCO2 during hyperoxia. 
Demonstration and Validation of Penumbra Detection 
Utilising OC T2* and Lactate Change GOLD Imaging 
Concurrently  
DWI/PI mismatch tissue (Figure 7A iii) was 
derived from coregistration of thresholded ADC 
(Figure 7A(i)) and CBF maps (Figure 7A(ii)) and used 
for comparison with penumbra identified using both 
T2* and lactate change OC techniques. 
Detection of T2* OC defined penumbra following O-PFC 
During the initial OC (~1.5 h post-MCAO) the 
magnitude of T2* signal change during both 50% and 
100% OC varied throughout the selected ROIs (Figure 
7A, iv and vi). In the ipsilateral hemisphere, the 
region defined as ischaemic core by thresholded ADC 
maps showed the smallest percentage change, while 
the thresholded T2*-defined penumbra displayed 





significantly greater changes during 50% and 100% 
OC (Figure 7A iv & vi, Figure 8A). When compared to 
the contralateral cortex, the thresholded T2*-defined 
penumbra displayed significantly greater changes to 
both levels of hyperoxia (Figure 7A iv & vi, Figure 
8A). Following a period when the animals were 
returned normoxic ventilation, similar results were 
evident during the second OC (~2.5 h post-MCAO, 
Figure 7B & 8B) with once again, significantly greater 
signal change evident in the T2*-defined penumbra 
ROI when compared to all other ROIs.  
 
 
Figure 7. Detection of penumbra from a representative animal using perfusion (ii) diffusion (i) mismatch (iii), and T2*OC (iv, v, vi and vii) at ~1.5 h (A) and ~2.5 h (B) 
following MCAO with prior administration of O-PFC (4.5 mL/kg). (i) ADC map prior to initial oxygen challenge; (ii) relative CBF map for the same slice and (iii) the 
corresponding DWI/PI mismatch (black shading) with selected ROIs superimposed (orange T2*OC penumbra; blue, mirror contralateral ROI; red, ischaemic core; 
and purple, mirror contralateral ROI). (iv) Thresholded T2*OC signal change map (%) using 50% O2 with (v) the corresponding thresholded image. (vi) and (vii), 
corresponding images using 100% O2. P = penumbra. ADC: apparent diffusion coefficient; CBF: cerebral blood flow; DWI: diffusion-weighted imaging; MCAO: middle 
cerebral artery occlusion; OC: oxygen challenge; PI: perfusion imaging; ROI: region of interest. 
 
Figure 8. T2* signal change to 50% and 100% oxygen challenges for selected ROIs carried out at (A) ~1.5 h and (B) ~2.5 h following MCAO. O-PFC was 
administered just prior to the initial oxygen challenge. Bars indicate means. * indicates significantly greater signal change (p<0.05) in T2*OC defined penumbra 
compared to all other ROI using one-way ANOVA followed by Bonferroni’s Multiple Comparison Test. Contra cortex, contralateral cortex; T2*OC penumbra, T2* 
oxygen challenge-defined penumbra; ADC core, ADC-defined ischaemic core; Contra caudate, contralateral caudate nucleus. ADC: apparent diffusion coefficient; 
MCAO: middle cerebral artery occlusion. 





At each time point, the volume of penumbra 
defined by T2*OC with O-PFC was similar for 50% 
and 100% OC (Figure 9). The animals were ventilated 
on air between the two OCs (normoxia) and it was 
notable that penumbra volume at ~2.5 h post-MCAO 
was significantly smaller than that detected at the 
earlier time point (Figure 9). 
 
 
Figure 9. Penumbra volume measured across the two slices (slice thickness, 
1.5 mm) used to analyse T2*OC responses. *p<0.05 **p<0.01. Indicates a 
significant reduction in penumbra volume from 1.5 h to 2.5 h post-MCAO. Data 
presented as mean ± SD, n=9. MCAO: middle cerebral artery occlusion. 
Simultaneous detection of penumbra from lactate change 
maps following O-PFC 
Elevated lactate levels were detected in the 
ischaemic hemisphere following stroke in Study 2. 
The O-PFC and hyperoxic challenge resulted in a 
decrease in ischaemia-induced lactate on lactate 
change maps in all animals. In the representative 
scans in Figure 10, a decrease in tissue lactate can be 
observed in response to an OC at ~2.5 h following 
MCAO (Figure 10 iii). In this example the region of 
lactate change closely approximates but is different to 
the DWI/PI mismatch region in the temporally 
matched DWI/PI image (Figure 10 vii). On returning 
back to normoxic ventilation, the lactate change map 
indicates an increase in lactate within this region 
(Figure 10 iv) and the thresholded ADC derived 
lesion has increased in size (Figure 10 viii). These 
regions of change in tissue lactate indicate that this 
hypoperfused tissue is still metabolically active as it 
retains the ability to switch between aerobic and 
anaerobic metabolism.  
Evidence of ongoing glucose use in regions identified as 
penumbra by GOLD imaging techniques 
[14C]2-deoxyglucose autoradiography confirmed 
maintained glucose use within the T2* and lactate 
change OC-defined penumbra. The ROI on the 
[14C]2-DG autoradiogram which mirrored penumbra 
 
 
Figure 10. Lactate change aerobic (i, iii) and anaerobic (ii, iv) maps following administration of O-PFC (4.5 mL/kg) with time matched DWI/PI mismatch images 
(v-viii) for the first (1.5 h post-MCAO) and second (2.5 h post-MCAO) OCs. Regions of increased (white regions) or decreased (black regions) lactate evident in 
images i-iv were similar to but not exactly matching the region of DWI-PI mismatch shown in black in images v-viii. The white region in images v-viii represents the 
thresholded ADC lesion representing the ischaemic core. ADC: apparent diffusion coefficient; DWI: diffusion-weighted imaging; MCAO: middle cerebral artery 
occlusion; OC: oxygen challenge; PI: perfusion imaging. 





defined by T2* signal change and lactate change maps 
displayed a level of glucose metabolism that was not 
different from the contralateral ROI (24.5 ± 8.0 mmol 
per 100 g per minute compared with 21.5 ± 6.6 mmol 
per 100 g per minute in contralateral cortex; Figure 
11). In contrast, glucose metabolism was markedly 
decreased in the ADC-defined ischaemic core in the 
majority of animals. In two animals where 100% O2 
hyperoxia was maintained throughout the duration of 
the 2-DG autoradiography protocol, elevated glucose 
use was identified within the ADC core ROI (Figure 
11), in an area distinct from the hyperglycolytic band 
previously described [15]. This is an interesting 
observation, which could support the use of 
prolonged periods of hyperoxia following O-PFC 
administration as a potential therapeutic approach in 
acute ischaemic stroke.  
 
 
Figure 11. Local cerebral glucose utilisation (LCMRglu) in regions of interest 
generated following the completion of the later T2*OC and Lactate Change OC 
maps (~3 h following MCAO). Individual animal data shown with horizontal line 




There has been an increased effort over recent 
years to develop advanced acute stroke brain imaging 
techniques that can metabolically delineate the 
ischaemic penumbra from the irreversibly damaged 
core and benign oligaemia (hypoperfused tissue 
destined to survive). This would enable significant 
improvements in the management of acute stroke 
patients by differentiating patients with viable brain 
tissue (therapeutic target) irrespective of time from 
stroke onset, from those who have largely irreversible 
damage at presentation and who could therefore be 
exposed to additional risk from reperfusion therapy. 
In this paper we have presented further preclinical 
validation of two complementary diagnostic MR 
imaging techniques, which when combined with 
intravenous O-PFC and OC, (GOLD imaging), have 
the potential to identify metabolically active 
penumbra in rodent models of acute stroke. Further 
studies (unpublished) demonstrating a concomitant 
therapeutic benefit of O-PFC and hyperoxia supports 
the true theranostic potential of this novel technology, 
for which initial clinical trials in acute stroke patients 
are planned for late 2017. 
The first studies to metabolically map the 
ischaemic penumbra following acute stroke used PET 
[28], the gold standard method identifying 
metabolically active brain tissue with reduced 
cerebral blood flow, an increased oxygen extraction 
fraction and a preserved cerebral metabolic rate of 
oxygen [29]. However due to a number of factors 
including lack of availability, extended scanning time 
and radiation exposure, PET has not been adopted for 
clinical use in acute stroke. Focus has therefore shifted 
towards the use of other, more widely available 
imaging modalities (MRI, CT Perfusion (CTP)) in the 
pursuit of providing physicians with a diagnostic tool 
to identify patients with metabolically active 
penumbra [30]. However, these techniques, which 
rely on selecting threshold values to define the DWI 
lesion and/or the perfusion deficit, do not provide 
direct information on metabolic activity. Neither have 
been validated and accepted for clinical use for 
routine for penumbra imaging, possibly because of a 
lack of consensus on threshold setting to accurately 
compartmentalise brain tissue into irreversibly 
damaged core, penumbra and benign oligaema. 
Indeed MR perfusion imaging, integral to DWI/PI 
mismatch, has been shown to be inherently poor in 
discriminating hypoperfused penumbra from benign 
oligaemia [10,11]. Furthermore, uncertainty remains 
around whether the thresholded DWI lesion truly 
represents irreversibly damaged core tissue since 
early DWI lesions have the capacity to display 
penumbral characteristics with evidence of reversal in 
response to acute reperfusion [31,32]. Early clinical 
studies (DIAS and DEDAS) investigating the 
thrombolytic drug desmoteplase, suggested that 
patients selected with DWI/PI mismatch 
demonstrated higher rates of reperfusion upon 
treatment initiated up to 9 h following symptom onset 
[33,34]. The subsequent DIAS II trial was the first 
phase 3 trial to include an estimate of DWI/PI 
mismatch as an indicator of penumbra in the 
inclusion criteria [30]. However the outcome of this 
trial was negative and much of the attention following 
this disappointing result, focussed on the criteria used 
to define penumbra. The DIAS II trial used a MR 
perfusion deficit that was ~20% larger compared 
against a time matched DWI lesion considered to be 
ischaemic core. Some patients were also selected in 
this study on the basis of a CTP deficit. In both 





instances this was done without applying appropriate 
perfusion thresholds to define penumbra. This 
combined with pooling of patients selected by both 
MR perfusion and CTP undoubtedly added to 
increased heterogeneity in the patients included and 
was retrospectively recognised to be inadequate in 
accurately selecting a patient population with true 
penumbra [35].  
Likewise CTP demonstrates a high degree of 
heterogeneity in the acquisition protocols and 
post-processing software and this lack of 
standardisation has resulted in the lack of established 
validated thresholds for the quantitative definition of 
the ischaemic penumbra [10,11]. Even with accurate 
quantitative measurement of blood flow, it is not 
possible to prospectively set a perfusion threshold for 
the ischaemic penumbra, as the amount of blood flow 
required to maintain tissue viability is not fixed but 
varies over time [36,37]. Using the time to peak and 
mean transit times as surrogate measures of perfusion 
to identify the penumbra lack precision, as 
intracranial collateral blood flow pathways vary 
across individuals and brain regions. A recent 
systematic review incorporating more than 2000 
patients across 27 studies was carried out to assess the 
diagnostic accuracy of CTP in acute ischemic stroke 
[38]. It concluded that more high quality evidence is 
required for CTP to be used as a diagnostic tool that 
can reliably inform on selection of stroke patients for 
treatment. A lack of agreement on CTP processing 
parameters, biologically significant perfusion 
parameters and thresholds applied for decision 
making were highlighted. All of this adds to 
variability in the sensitivity of the technique and 
increases the uncertainty in the accuracy of its use in 
directing important treatment decisions [39,40,41].  
MR perfusion and CTP were also used to select 
patients in clinical trials assessing endovascular 
therapy. In the MR RESCUE trial a lack of correlation 
between penumbral pattern on neuroimaging and 
outcome in terms of benefit from endovascular 
therapy was demonstrated [42]. As discussed in a 
recent meta-analysis [43], further clinical studies on 
endovascular recanalisation therapy have proven the 
technique to be of benefit in patients with large vessel 
ischaemic stroke. In general, the trials included within 
this meta-analysis utilised brain imaging such as CTP 
to exclude patients with large ischaemic cores who 
would have been less likely to have a good outcome. 
Current trials on thrombolytic therapy (ECASS-4) and 
endovascular thrombectomy (DEFUSE 3) are further 
investigating the use of MR and CT to select patients 
on the basis of penumbral patterns from brain 
imaging [(44]; NCT02586415). 
Therefore it is clear that, at present, these 
techniques require further refinement and 
optimisation to identify potential responders to 
reperfusion therapy beyond the currently 
recommended time windows. Furthermore, as they 
don’t provide a metabolic approximation of 
penumbra their clinical utility in this regard will 
remain open to question.  
The objective of the studies presented here was 
to advance the development of two complementary 
metabolically MRI based neuroimaging techniques 
(T2* and Lactate Change sequences combined with 
OC and O-PFC = GOLD imaging) for diagnostic use 
in the acute stroke setting to determine the presence of 
salvageable penumbra based on the metabolic status 
of this tissue.  
Proof-of-concept for detection of penumbra was 
initially established for both techniques using 100% 
oxygen alone in rodent stroke models [13,14] with the 
T2*OC already translated to 3T clinical scanners and 
tested in healthy volunteers and stroke patients [18]. 
However, signal-to-noise was poor with the T2*OC on 
translation to the clinical scanner and 100% oxygen 
inhalation resulted in spatial distortion of 
T2*-weighted contrast and significant artefacts within 
the human forebrain (due to paramagnetic oxygen in 
airways and nasal sinuses).  
It is “change” in tissue lactate to an oxygen 
challenge, not absolute lactate levels, that are 
important in assessing “metabolic integrity” (or 
salvageability). Our group previously developed the 
novel method of lactate change MRI, which is based 
on imaging changes in brain tissue lactate levels in 
response to hyperoxic challenges [14]. This metabolic 
method reflects capacity of tissue to switch between 
anaerobic to aerobic metabolism when additional 
oxygen is delivered. This would happen only if the 
mitochondria are functioning and so can produce the 
necessary ATP (38 ATPs generated with aerobic 
metabolism vs 2 ATPs with anaerobic metabolism for 
every molecule of glucose) to maintain cell function. 
Cell energetics are key to the survival of ischaemic 
tissues. Therefore, by identifying tissues with 
anaerobic metabolism but with a capacity to utilise 
oxygen and capability for aerobic metabolism, OC 
lactate change imaging, identifies salvageable 
penumbral tissue. Lactate Change OC proof of 
principle was also demonstrated with 100% oxygen 
alone but again there were limitations regarding 
sensitivity and the need for long scan times to observe 
lactate change [14]. 
The primary aim of Study 1 was to evaluate 
whether addition of a PFC improved the sensitivity 
and reduced the time for the Lactate Change OC, 
making the technique an applicable tool in the clinical 
setting. The data presented in Figures 3-5 provide 





evidence of further improvements in the technique 
through prior administration of b-PFC with changes 
in tissue lactate specific to the penumbra voxel being 
seen following hyperoxic challenge in the animals 
receiving b-PFC. During hyperoxia, lactate levels in 
the penumbra voxel showed a trend for an overall 
increase in the control saline group (3 animals showed 
increase, 2 no change and 3 showed a decrease). This 
is indicative of a continued switch to anaerobic 
metabolism in the hypoperfused penumbra tissue, 
resulting in further increases in tissue lactate levels. It 
also confirms that normobaric hyperoxia alone is not 
always sufficient in this model to improve 
oxygenation of the penumbra to the extent that 
aerobic metabolism is restored. However, in the 
group of animals receiving b-PFC, lactate levels in the 
penumbra voxel were decreased in all animals and 
significantly reduced after 10 minutes of hyperoxia. It 
is known that PFC micelles are 1/30th – 1/40th the size 
of red blood cells (diameter of about 200 nanometers) 
and are therefore able to penetrate the smallest blood 
vessels, enabling oxygen delivery to ischaemic tissues. 
This along with an improved extraction ratio of 
oxygen from PFC emulsions when compared to 
haemoglobin [45] could improve oxygen delivery 
such that there is a switch back to aerobic metabolism 
with the resulting decrease in tissue lactate. This 
provides validation that intravenous PFC increases 
the sensitivity of our Lactate Change OC diagnostic 
technique in detection of penumbra compared to 
normobaric hyperoxia alone and has the potential to 
translate into clinical application, as the change can be 
imaged with shorter scanning time. No changes in 
lactate levels were observed in either the ischaemic 
core or contralateral voxels in either group. This is 
likely to be due to tissue within the ischaemic core 
being unable to recover aerobic metabolism despite 
the increased delivery of oxygen during hyperoxia 
(i.e. tissue is no longer metabolically active). The lack 
of effect in the contralateral caudate nucleus is likely 
to be a reflection of little or no increase in lactate level 
within this region of the brain acutely following 
stroke. 
We next investigated the potential of combining 
the metabolic GOLD imaging techniques (T2*OC and 
Lactate Change OC) within a single scanning protocol 
using O-PFC. The protocol was designed such that 
T2*OC and Lactate Change OC imaging could be 
applied concurrently in the same scanning session in a 
way that would most likely mimic the intended 
clinical utility of these imaging techniques in the acute 
stroke setting.  
For lactate change imaging, the example shown 
in Figure 10 indicates that during the initial OC, at 
~1.5 h post-MCAO there is a small increase rather 
than decrease in lactate within the ipsilateral 
hemisphere (Figure 10 i) in a region close to the 
ischaemic core when comparing to the time-matched 
ADC lesion (Figure 10 v). It may be that in this 
particular animal tissue lactate levels are rapidly 
increasing at this time, in response to the ischaemic 
insult, making it difficult to image a decrease in 
response to hyperoxia. On returning to normoxia a 
further increase in tissue lactate levels was observed 
in the ipsilateral hemisphere (Figure 10 ii). However, 
in response to the second OC at ~2.5 h post-MCAO 
there was a clear decrease in tissue lactate observed in 
an ipsilateral region, similar to but not identical in size 
and location to DWI/PI mismatch (Figure 10 iii and 
vii). This decrease in tissue lactate provides evidence 
of tissues that are hypoperfused and under metabolic 
stress but that retain the capacity to respond to 
increased oxygen delivery by switching to aerobic 
metabolism. The earliest sign of cellular injury is 
neuronal swelling or shrinkage and micro- 
vacuolation of the cytoplasm, which is associated with 
mitochondrial swelling. These changes are reversible. 
Once the mitochondrial membranes rupture then the 
process is irreversible. The membrane potentials are 
maintained by ion pumps, the most important being 
the Na+/K+ ATPase and these require energy. 
Anaerobic metabolism of glucose only provides 2 
ATPs from a molecule of glucose but with aerobic 
metabolism one molecule of glucose can provide 
additional 36 ATPs. The energy produced by 
anaerobic metabolism cannot sustain the membrane 
potentials and this lack of energy ultimately results in 
cell death. As long as the mitochondria are functional 
and able to utilise oxygen to generate ATP, the neuron 
will have the energy to survive. Therefore the 
ischaemic penumbra represents hypo-perfused tissue 
displaying anaerobic metabolism due to lack of 
oxygen, which still has the potential for aerobic 
metabolism and so is potentially salvageable.  
The results presented in Study 2 utilising 
spectroscopic imaging of lactate to map lactate change 
in response to hyperoxic challenge following O-PFC 
administration, corroborate with the results from 
Study 1 where b-PFC was shown to improve the 
possibility to detect decreases in the lactate spectral 
peak. Together these findings substantiate an 
enhancement by PFC to delineate metabolically active 
penumbra using this technique. Furthermore the 
ability to detect regions of lactate change in all 
animals analysed in Study 2 signifies an improvement 
in the sensitivity to detect lactate change, through the 
addition of O-PFC emulsion. Previously published 
findings reported a decrease in tissue lactate in only a 
subset of animals when using 100% O2 alone [14].  
To address limitations encountered during 





preliminary translation of the T2*OC technique an 
intravenous PFC was administered prior to OC with 
lower oxygen levels. Following administration of our 
b-PFC, lower level hyperoxia (40-50% O2) significantly 
enhanced T2* signal change in the ischaemic 
penumbra ROI compared with lower oxygen levels 
alone [21]. Study 2 results provide confirmation of this 
finding with intravenous O-PFC emulsion, which is 
the PFC product intended for subsequent clinical 
studies. The magnitude of T2* signal change in 
penumbra was consistent with our previous study. 
This validates the use of O-PFC in combination with 
low-level hyperoxia for enhancing the T2*OC method, 
which should overcome both artefact and signal to 
noise issues encountered in early clinical studies. 
Indeed upon quantification of the region identified as 
penumbra by thresholded T2*OC signal change maps, 
there was no difference in the volume detected by 
either 50% or 100% oxygen providing further support 
for increased sensitivity at lower levels of inhaled 
oxygen with the addition of O-PFC. It was however 
notable from Study 2 that the volume of the region 
detected as penumbra during the later T2*OC at ~2.5 h 
post-MCAO, was significantly smaller than that 
detected at the earlier time point. This indicates a 
progression of the ischaemic damage and 
incorporation of penumbral tissue into ischaemic core 
between the two OCs when animals were ventilated 
with air. This provides additional validation that the 
technique identifies ischaemic penumbra and also 
that in the absence of hyperoxia, O-PFC was limited in 
its capacity to maintain penumbra viability. 
In meeting the objective of Study 2, both GOLD 
imaging techniques, T2*OC and Lactate Change OC, 
were successfully run within the same scanning 
protocol, working concurrently to identify penumbra 
following administration of O-PFC. Example images 
showing penumbra identified by both techniques 
running concurrently in the same animal are 
illustrated in Figure 12. It is evident that regions 
identified as penumbra on T2*OC (Figure 12 i) and 
Lactate Change OC maps (Figure 12 iii and iv) were 
not identical to each other or to the region defined by 
DWI/PI mismatch (Figure 12 ii). The T2*OC identifies 
hypoperfused tissues with oxygen utilisation and an 
increased oxygen extraction fraction whilst the 
Lactate Change OC imaging identified hypoperfused 
tissues displaying anaerobic metabolism but having 
the potential for aerobic metabolism. 
Both these techniques are assessing 
different aspects of metabolism and 
therefore it is not surprising they 
were not identical as shown in our 
study.  
A final objective of this study 
was to provide validation of the 
combined techniques by confirming 
on-going tissue glucose metabolism 
in hypoperfused regions of the brain 
identified as penumbra by both T2* 
and lactate change OC. Terminal [14C] 
2-deoxyglucose autoradiograms, 
confirmed glucose metabolism within 
both the T2*OC-defined and the 
Lactate Change OC identified 
penumbra. Therefore, both 
techniques are complementary and 
further studies will help define their 
individual advantages and 
disadvantages.  
It was notable that when 
ventilation was switched back from 
100% oxygen to air in Study 1 that 
lactate levels significantly increased 
in the saline group at 30 minutes 
while the decreased lactate levels 
were maintained below 
pre-hyperoxia baseline values in the 
b-PFC group. This suggests that 
 
Figure 12. Matched images illustrating both T2*OC and Lactate Change OC GOLD penumbra 
techniques working simultaneously in a representative animal following administration of O-PFC (~4.5 
mL/kg). (i) T2* signal change map to 50% OC at ~2.5 h post MCAO. (ii) corresponding time-matched 
DWI/PI mismatch. (iii) Aerobic lactate change map in response to 50% OC at ~3 h post MCAO and (iv) 
anaerobic lactate change map in response to returning animal to normoxic ventilation at ~3 h 
post-MCAO. P, penumbra. DWI: diffusion-weighted imaging; GOLD: Glasgow Oxygen Level Dependent; 
MCAO: middle cerebral artery occlusion; OC: oxygen challenge; PI: perfusion imaging. 





animals given b-PFC could maintain aerobic 
metabolism in the penumbra voxel, presumably 
through more efficient delivery of oxygen to this 
tissue unlike the control animals receiving saline. Due 
to the small size of the PFC nanoparticles (35-45 times 
smaller than red blood cells) they have the capacity to 
reach the microcirculation beyond an occluding clot in 
any remaining plasma flow, or via collaterals, thereby 
improving delivery of oxygen to the compromised 
ischaemic penumbra. It has been shown that ischemia 
induces sustained contraction of pericytes on 
microvessels and thereby causes capillary constriction 
and obstruction of erythrocyte flow [46]. PFC 
nanoparticles (~0.2 μm compared to ~7 μm for 
erythrocytes) could therefore improve delivery of 
oxygen within this compromised microcirculation.  
Initial evidence for the ability of PFC to support 
the ischaemic penumbra and offer therapeutic 
potential following acute ischaemic stroke comes 
from analysis of lesion growth in Study 1. In addition 
to measuring lactate, a secondary aim of this study 
was to quantify the area of ischaemic damage from 
thresholded ADC maps during the period of 
hyperoxia and return to normoxia. It was shown that 
lesion expansion during this period was significantly 
smaller in the group of animals receiving b-PFC when 
compared to the group receiving saline prior to 
hyperoxia. This suggests that animals given b-PFC in 
combination with hyperoxia could maintain aerobic 
metabolism because of functioning mitochondria and 
the resulting cell energetics would support the 
survival of penumbral tissue.  
In summary enhancement of both GOLD 
imaging techniques following intravenous O-PFC and 
hyperoxia has been demonstrated for the first time in 
vivo, working concurrently to identify the metabolic 
penumbra in a rodent stroke model. Regions 
identified as penumbra with both T2*OC and Lactate 
Change OC techniques displaying maintained glucose 
metabolism. Further development of co-registration 
and analysis software to provide a penumbra map on 
clinical MRI scanners is ongoing.  
Successful translation of GOLD imaging would 
enable treatment decisions and recruitment into 
future acute stroke trials investigating efficacy 
endpoints to be based on metabolic status of the brain 
tissue independent of time from stroke onset. This 
could improve the safe use and extend the availability 
of current therapeutic options to many more acute 
stroke patients. We have also uncovered preliminary 
evidence for a potential therapeutic benefit of O-PFC 
plus hyperoxia during scanning, which could offer 
significant advantages over current penumbral 
imaging techniques by slowing the progression of 
ongoing ischaemic damage. Further therapeutic 
benefit could be realised by extending hyperoxia 
beyond the scanning period and this is the focus of 
additional research by our group. Therefore, through 
unique simultaneous diagnostic and therapeutic 
application in acute ischaemic stroke, GOLD imaging 
technology incorporating intravenous O-PFC and 
hyperoxia offers new hope in improving the 
management of acute stroke patients. 
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